Future analyses should examine cohorts that include a greater percentage of patients with lymph node-positive or metastatic disease to determine if GDF15 overexpression is associated with metastasis, recurrence, or reduced survival rates in patients with advanced-stage disease, as is reported in other tumor types [32, 33]. This evidence concerns the gene GDF15 and neoplasm.